🚀 VC round data is live in beta, check it out!
Gubra Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gubra and similar public comparables like Fortrea, Oxford BioMedica, PolyPeptide, R&G PharmaStudies and more.
Gubra Overview
About Gubra
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
Founded
2008
HQ
Employees
260
Website
Financials (LTM)
EV
$564M
Gubra Financials
Gubra reported last 12-month revenue of $327M and EBITDA of $250M.
In the same LTM period, Gubra generated $316M in gross profit, $250M in EBITDA, and $192M in net income.
Revenue (LTM)
Gubra P&L
In the most recent fiscal year, Gubra reported revenue of $417M and EBITDA of $341M.
Gubra expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $327M | XXX | $417M | XXX | XXX | XXX |
| Gross Profit | $316M | XXX | $394M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $250M | XXX | $341M | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 82% | XXX | XXX | XXX |
| EBIT Margin | 75% | XXX | 81% | XXX | XXX | XXX |
| Net Profit | $192M | XXX | $263M | XXX | XXX | XXX |
| Net Margin | 59% | XXX | 63% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gubra Stock Performance
Gubra has current market cap of $969M, and enterprise value of $564M.
Market Cap Evolution
Gubra's stock price is $59.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $564M | $969M | -0.1% | XXX | XXX | XXX | $16.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGubra Valuation Multiples
Gubra trades at 1.7x EV/Revenue multiple, and 2.3x EV/EBITDA.
EV / Revenue (LTM)
Gubra Financial Valuation Multiples
As of April 8, 2026, Gubra has market cap of $969M and EV of $564M.
Equity research analysts estimate Gubra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gubra has a P/E ratio of 5.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $969M | XXX | $969M | XXX | XXX | XXX |
| EV (current) | $564M | XXX | $564M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 2.3x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBIT | 2.3x | XXX | 1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | 1.4x | XXX | XXX | XXX |
| P/E | 5.0x | XXX | 3.7x | XXX | XXX | XXX |
| EV/FCF | 4.2x | XXX | 2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gubra Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gubra Margins & Growth Rates
Gubra's revenue in the last 12 month declined by (73%).
Gubra's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.2M for the same period.
Gubra's rule of 40 is (80%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gubra's rule of X is (201%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gubra Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (73%) | XXX | (81%) | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 82% | XXX | XXX | XXX |
| EBITDA Growth | (97%) | XXX | (100%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (80%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (201%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gubra Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fortrea | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford BioMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPeptide | XXX | XXX | XXX | XXX | XXX | XXX |
| R&G PharmaStudies | XXX | XXX | XXX | XXX | XXX | XXX |
| AbCellera | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gubra M&A Activity
Gubra acquired XXX companies to date.
Last acquisition by Gubra was on XXXXXXXX, XXXXX. Gubra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gubra
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGubra Investment Activity
Gubra invested in XXX companies to date.
Gubra made its latest investment on XXXXXXXX, XXXXX. Gubra invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gubra
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gubra
| When was Gubra founded? | Gubra was founded in 2008. |
| Where is Gubra headquartered? | Gubra is headquartered in Denmark. |
| How many employees does Gubra have? | As of today, Gubra has over 260 employees. |
| Who is the CEO of Gubra? | Gubra's CEO is Henrik Blou. |
| Is Gubra publicly listed? | Yes, Gubra is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Gubra? | Gubra trades under GUBRA ticker. |
| When did Gubra go public? | Gubra went public in 2023. |
| Who are competitors of Gubra? | Gubra main competitors are Fortrea, Oxford BioMedica, PolyPeptide, R&G PharmaStudies. |
| What is the current market cap of Gubra? | Gubra's current market cap is $969M. |
| What is the current revenue of Gubra? | Gubra's last 12 months revenue is $327M. |
| What is the current revenue growth of Gubra? | Gubra revenue growth (NTM/LTM) is (73%). |
| What is the current EV/Revenue multiple of Gubra? | Current revenue multiple of Gubra is 1.7x. |
| Is Gubra profitable? | Yes, Gubra is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gubra? | Gubra's last 12 months EBITDA is $250M. |
| What is Gubra's EBITDA margin? | Gubra's last 12 months EBITDA margin is 77%. |
| What is the current EV/EBITDA multiple of Gubra? | Current EBITDA multiple of Gubra is 2.3x. |
| What is the current FCF of Gubra? | Gubra's last 12 months FCF is $135M. |
| What is Gubra's FCF margin? | Gubra's last 12 months FCF margin is 41%. |
| What is the current EV/FCF multiple of Gubra? | Current FCF multiple of Gubra is 4.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.